Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.80 |
| ▸ | SHBG | P04278 | 3/20 | 0.80 |
| ▸ | AR | P10275 | 5/20 | 0.79 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.67 |
| ▸ | PGR | P06401 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | SNCA | P37840 | 2/20 | 0.67 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.67 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.67 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6Beta-Hydroxytestosterone SCHEMBL135030 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP19A1SHBGARLMNA | |
| 6Beta-Hydroxytestosterone SCHEMBL4122472 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP19A1SHBGARLMNA | |
| 6Beta-Hydroxytestosterone SCHEMBL3278189 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP19A1SHBGARLMNA | |
| 6Beta-Hydroxytestosterone SCHEMBL14067596 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP19A1SHBGARLMNA | |
| 6Beta-Hydroxytestosterone SCHEMBL28056047 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP19A1SHBGARLMNA | |
| 6Beta-Hydroxytestosterone SCHEMBL13752809 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP19A1SHBGARLMNA | |
| SCHEMBL11524096 | 0.89 | CYP19A1 (1.00) | CYP3A4CYP19A1SHBGARLMNA | |
| SCHEMBL6006777 | 0.89 | CYP19A1 (1.00) | CYP3A4CYP19A1SHBGARLMNA | |
| SCHEMBL10273241 | 0.89 | CYP19A1 (1.00) | CYP3A4CYP19A1SHBGARLMNA | |
| SCHEMBL5021333 | 0.89 | CYP19A1 (1.00) | CYP3A4CYP19A1SHBGARLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120111795-A1 | DIFFERENTIATED HUMAN LIVER CELL CULTURES AND THEIR USE IN BIOARTIFICIAL LIVER SYSTEMS | ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2012-05-10 | — | — | US | claimed |
| EP-2421954-A1 | DIFFERENTIATED HUMAN LIVER CELL CULTURES AND THEIR USE IN BIOARTIFICIAL LIVER SYSTEMS | Academisch Ziekenhuis bij de Universiteit van Amsterdam (NL) | 2012-02-29 | — | — | EP | claimed |
| WO-2010123357-A1 | DIFFERENTIATED HUMAN LIVER CELL CULTURES AND THEIR USE IN BIOARTIFICIAL LIVER SYSTEMS | ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2010-10-28 | — | — | WO | claimed |
| US-20090117612-A1 | METHOD OF BIOOXIDATION USING AN OLD YELLOW ENZYME | GLIEDER ANTON | 2009-05-07 | — | — | US | claimed |
| WO-2008137789-A1 | METHOD OF BIOOXIDATION USING AN OLD YELLOW ENZYME | CODEXIS, INC. (US) | 2008-11-13 | — | — | WO | claimed |
| US-12528812-B2 | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | GENENTECH, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12247032-B2 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of JAK kinases | GENENTECH, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| CN-114026096-B | Tetrazole-substituted pyrazolopyrimidine JAK kinase inhibitor and application thereof | 豪夫迈·罗氏有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-114008050-B | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | 豪夫迈·罗氏有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240279612-A1 | LIVER ORGANOID MANUFACTURING METHODS, LIVER ORGANOIDS OBTAINED WITH THE SAME, AND USES THEREOF | HCS PHARMA (FR) | 2024-08-22 | — | — | US | disclosed |
| CN-114008051-B | Pyrazolopyrimidine sulfone inhibitors of JAK kinases and uses thereof | 豪夫迈·罗氏有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2024123700-A1 | HISTONE DEACETYLASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2001011035-A9 | MONOCLONAL ANTIBODIES FOR HUMAN CYTOCHROME P450 3A4 AND HUMAN CYTOCHROME P450 2C9 | MERCK & CO INC (US) | 2002-07-11 | — | — | WO | disclosed |
| EP-1206530-A1 | MONOCLONAL ANTIBODIES FOR HUMAN CYTOCHROME P450 3A4 AND HUMAN CYTOCHROME P450 2C9 | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1180546-A1 | HUMAN CELL LINE SHOWING STABLE EXPRESSION OF CYTOCHROMES P450 | Takeda Chemical Industries, Ltd. (JP) | 2002-02-20 | — | — | EP | disclosed |
| US-6300476-B1 | ENZYME INHIBITOR; FOR USE IN TREATMENT OF LIVER DEFECTS | MERCK & CO., INC. | 2001-10-09 | — | — | US | disclosed |
| WO-2001011035-A1 | MONOCLONAL ANTIBODIES FOR HUMAN CYTOCHROME P450 3A4 AND HUMAN CYTOCHROME P450 2C9 | MERCK & CO., INC. (US) | 2001-02-15 | — | — | WO | disclosed |
| EP-1011708-A1 | ANTI-PEPTIDE ANTIBODY AGAINST HUMAN CYTOCHROME P450 3A4 | Merck & Co., Inc. (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998044939-A1 | ANTI-PEPTIDE ANTIBODY AGAINST HUMAN CYTOCHROME P450 3A4 | MERCK & CO., INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998017667-A1 | 6',7'-DIHYDROXYBERGAMOTTIN, A CYTOCHROME P450 IHNIBITOR IN GRAPEFRUIT JUICE | WAYNE STATE UNIVERSITY (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528812-B2 | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | JAK1, JAK2, CNKSR1 | CYP3A4 2186/4885CYP19A1 1813/4885SHBG 4602/4885 |
| US-12247032-B2 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of JAK kinases | JAK1, JAK2, JAK3 | CYP3A4 2137/4885CYP19A1 1998/4885SHBG 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.